Based on these studies, we inferred that small-molecule drugs targeting key cellular signaling pathways, including MAPK, PI3K/Akt, and Hippo, could serve as conjunctions with oncoVV-AVL to promote breast cancer therapy. This evidence concerns the gene AKT1 and breast cancer.